EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
The human ortholog was chosen for its high sequence identity (87%, 274/315) and conserved secondary structure (RSMD = 0.220), ensuring functional equivalence to KIN-19 (Supplementary Fig
As a medication, we applied BPC 157 (10 g/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone and/or combined, intravenously, immediately after intravenous heparin administration, while controls received simultaneously an equivolume of saline (0.5 ml/kg intravenously)
You should always follow the instructions given by your prescribing clinician, clinic, or pharmacy
Download the Full PDF Report (44 pages) Explore the Complete Session Data What this means for pharma teams Building a competitive intelligence package of this depth on a development-stage obesity drug typically requires a team of analysts spending two to four weeks